MARKET

ANIK

ANIK

Anika Therapeutics Inc
NASDAQ
31.56
+0.09
+0.29%
After Hours: 31.56 0 0.00% 16:01 12/02 EST
OPEN
31.27
PREV CLOSE
31.47
HIGH
31.76
LOW
30.97
VOLUME
95.69K
TURNOVER
0
52 WEEK HIGH
41.19
52 WEEK LOW
19.95
MARKET CAP
461.08M
P/E (TTM)
-29.0822
1D
5D
1M
3M
1Y
5Y
Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $31 Price Target
Benzinga · 11/09 14:26
--Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Price Target is $31
--Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Price Target is $31
MT Newswires · 11/09 09:35
Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue Estimates
Anika (ANIK) delivered earnings and revenue surprises of -20.83% and 10.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09 00:35
BRIEF-Anika Therapeutics Inc Reports Quarterly Loss Per Share Of $0.29
Reuters · 11/08 23:04
Anika Therapeutics Non-GAAP EPS of -$0.05 beats by $0.18, revenue of $40.3M beats by $2.71M
Seekingalpha · 11/08 21:40
Anika Therapeutics Q3 EPS $(0.05) Beats $(0.25) Estimate, Sales $40.26M Beat $37.59M Estimate
Benzinga · 11/08 21:12
Anika Reports Third Quarter Fiscal 2022 Financial Results
Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Si...
GlobeNewswire · 11/08 21:05
-- Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q3 Revenue $40.3M, vs. Street Est of $37.6M
-- Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q3 Revenue $40.3M, vs. Street Est of $37.6M
MT Newswires · 11/08 16:40
More
About ANIK
Anika Therapeutics, Inc. is a joint preservation company that creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. The Company is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

Webull offers kinds of Anika Therapeutics Inc stock information, including NASDAQ:ANIK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIK stock methods without spending real money on the virtual paper trading platform.